{"entity":{"id":"ander-urruticoechea","kind":"person","name":"Ander Urruticoechea","aka":[],"tldr":"Medical oncologist from Gipuzkoa who became President of GEICAM, Spain's academic breast cancer research group, in 2025 on the retirement of its founder Miguel Martín.","summary":"Ander Urruticoechea is President of GEICAM (Grupo Español de Investigación en Cáncer de Mama), the Spanish academic breast cancer research group. He took over the presidency in 2025 following the retirement of Miguel Martín, who had led the group for some 30 years after founding it with other oncologists. He is a medical oncologist at the Unidad de Oncología de Guipúzcoa (Osakidetza, the Basque health service) and a researcher at the Biogipuzkoa Health Research Institute. In a May 2025 interview he set out the challenge of sustaining academic breast cancer research without public funding and said he favours shared rather than single-person models of leadership.","asOf":"2026-09-10","links":[{"label":"Source: iSanidad interview naming him GEICAM president (May 2025)","url":"https://isanidad.com/330649/el-dr-urruticoechea-tomas-las-riendas-de-geicam-con-el-reto-de-sostener-la-investigacion-academica-en-cancer-de-mama-sin-apoyo-publico/"}],"tags":["leadership","professional-society","clinician-scientist"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["geicam"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["miguel-martin"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Presidente (President) of GEICAM, the Spanish Breast Cancer Group","institutionId":"geicam","specialisms":["Medical oncology","Breast cancer","Academic clinical research"],"profiles":[{"label":"iSanidad interview on taking over the GEICAM presidency (May 2025)","url":"https://isanidad.com/330649/el-dr-urruticoechea-tomas-las-riendas-de-geicam-con-el-reto-de-sostener-la-investigacion-academica-en-cancer-de-mama-sin-apoyo-publico/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Urruticoechea+A%5BAuthor%5D"}],"papers":[{"title":"Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy","journal":"Journal of Clinical Oncology","year":2017,"doi":"10.1200/jco.2016.70.6267"},{"title":"Proliferation Marker Ki-67 in Early Breast Cancer","journal":"Journal of Clinical Oncology","year":2005,"doi":"10.1200/jco.2005.07.501"},{"title":"A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study","journal":"Oncotarget","year":2017,"doi":"10.18632/oncotarget.17113"}]},"route":"/people/ander-urruticoechea/","neighbours":{"company":[{"id":"geicam","kind":"company","name":"GEICAM Spanish Breast Cancer Group","route":"/companies/geicam/"}],"person":[{"id":"miguel-martin","kind":"person","name":"Miguel Martín","route":"/people/miguel-martin/"}]}}